- Yale UrologyYale Physicians Building800 Howard AvenueNew Haven, CT 06519
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
Michael S. Leapman, MD, MHS
Biography
Michael S. Leapman, MD, who specializes in prostate, bladder, testicular and kidney cancers, loves his work as a urologic oncologist.
“Every day, I have the ability to make a difference in a patient's life,” says Dr. Leapman. “It's a tremendous honor and responsibility, and it's very rewarding.”
A member of Yale Cancer Center, he sees patients at Smilow Cancer Hospital and the West Haven Veteran’s Administration. An assistant professor of urology at Yale School of Medicine, he studies the best treatments for prostate cancer and how gene expression signatures can predict the aggressiveness of this cancer.
“Hearing the emotionally wrought words ‘it’s cancer’ is extremely difficult to navigate,” he says. “So that's one of the issues that we are sensitive to, and continue to strive to improve.”
The patient-physician bond is essential in helping patients with prostate cancer, for example, to choose which kind of treatment is best: surgery, radiation therapy or active surveillance, an ongoing monitoring of what can be a slow-progressing disease.
“It really is a very special relationship between a urologist and a patient. I have found that the team at Yale is 100 percent invested in the outcomes of our patients, and we stand out by seeking to understand their concerns, goals by being there for them every step of the way.”
Titles
- Associate Professor of Urology
- Clinical Program Leader, Prostate & Urologic Cancers Program, Yale Cancer Center
- Assistant Professor, Chronic Disease Epidemiology
Education & Training
- MHSYale University (2022)
- FellowshipUniversity of California San Francisco (2016)
- ResidencyMount Sinai Medical Center (2014)
- InternshipMount Sinai Medical Center (2010)
- MDUniversity of Maryland School of Medicine (2009)
- BACornell University (2005)
Additional Information
- John N. Forrest Jr. Prize for Mentorship in Student Research: (2022)
- Best Poster: European School of Oncology, Conference on Active Surveillance (2016)
- Merit Award: Conquer Cancer Foundation of the American Society of Clinical Oncology (2015)
- First Place Essay, History Section: American Urological Association Western Section (2015)
- Joseph F. McCarthy Physician Essay Contest, Third Place: American Urological Association Western Section (2015)
- Outstanding Abstract Selected for Oral Presentation: University of California San Francisco (2015)
- Resident Publication Award: Mount Sinai Medical Center, Department of Urology (2014)
- Resident Travel Award: Society for Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (2013)
- AB of Urology, Urology (2018)
- Leapman M, Rothen J, Long J, Kim I, Mitchell A, Yu J, Dinan M, Gross C, Ma X. Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer. JAMA Oncology 2026, 12 PMID: 42096231, PMCID: PMC13154023, DOI: 10.1001/jamaoncol.2026.0893.
- Palencia P, Xi X, Zhao X, Ward B, Smani S, Sivanesan N, Diaz G, Miszczyk M, Fazekas T, Rajwa P, Cavallo J, Aneja S, An Y, Kim I, Leapman M. Association Between Perirectal Spacer Use and Short-Term Complications Following Prostate Radiation Therapy in a National Claims Based Analysis. Urology Practice 2026, 101097upj0000000000000996. PMID: 41810984, DOI: 10.1097/upj.0000000000000996.
- Ajjawi I, Kim I, Smani S, Palencia P, Diaz G, Lee W, Kim I, Sprenkle P, Leapman M. Machine learning approaches to optimize the integration of sociodemographic factors for predicting cancer-specific survival among patients with high-risk prostate cancer. Current Urology 2026 DOI: 10.1097/cu9.0000000000000335.
- Lim D, Cavallo J, Leapman M, Ghodoussipour S, Kim I. Comprehensive Outcome Analysis of Single-Port Robot-Assisted Radical Prostatectomy. Journal Of Endourology 2026, 40: 321-327. PMID: 41314953, DOI: 10.1177/08927790251400364.
- Ajjawi I, Sprenkle P, Renzulli J, Leapman M. Re-evaluating the Role of Locoregional Therapy in Metastatic Prostate Cancer: A Review of Current Evidence and Evolving Clinical Approaches. Urologic Clinics Of North America 2026 DOI: 10.1016/j.ucl.2026.02.002.
- Miszczyk M, Sohoni N, Smani S, Moll M, Alfarhan A, Roessler N, Miyajima K, Inoue S, Marvaso G, Mastroleo F, Zamboglou C, Soeterik T, Zilli T, Terlizzi M, Blanchard P, Rajwa P, Fazekas T, Ploussard G, An Y, Leapman M, Blanck O, Jereczek-Fossa B, Shariat S. Efficacy and tolerability of hypofractionated and dose-boosted radiotherapy for localised prostate cancer: a systematic review and meta-analysis. Radiotherapy And Oncology 2026, 218: 111445. PMID: 41713502, DOI: 10.1016/j.radonc.2026.111445.
- Smani S, Sohoni N, Miszczyk M, Fazekas T, Rajwa P, Grimshaw A, Sundaresan V, Lokeshwar S, Weinreb J, Sprenkle P, Cooperberg M, Seibert T, Shariat S, Catalona W, Leapman M. Association between baseline prostate MRI PI-RADS classification and risk of Gleason upgrade during active surveillance: a systematic review and meta-analysis. World Journal Of Urology 2026, 44: 169. PMID: 41691567, DOI: 10.1007/s00345-026-06278-4.
- Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Spilberg G, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Rivera D, Kluetz P, Karnes R, Dinan M, Mitchell A, Kunst N, Wang S, Ma X, Gross C. Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States. JCO Oncology Practice 2026, op2500617. PMID: 41632928, DOI: 10.1200/op-25-00617.
- Kim I, Puri D, Rathi N, Leapman M, Kim I. Lack of survival benefit of pelvic lymph node dissection for patients with radical prostatectomy and postprostatectomy radiotherapy. Urologic Oncology Seminars And Original Investigations 2026, 44: 110985. PMID: 41576629, DOI: 10.1016/j.urolonc.2025.110985.
- Sohoni N, Sohoni N, Sutherland R, Sundaresan V, Smani S, Ananth P, Onofrey J, Aneja S, Miszczyk M, Lee H, Olivieri J, Leapman M. Automated Classification of Adverse Events After Hydrogel Perirectal Spacer Insertion for Prostate Cancer Using Large Language Models. Urology 2026, 209: 18-24. PMID: 41565161, DOI: 10.1016/j.urology.2026.01.008.
- Souroujon Torun A, Sundaresan V, Golos A, Leapman M, Gomez-Santamaría O, Casilla-Lennon M. The role of nutrition in prostate cancer risk, progression, and mortality: A comprehensive review. Clinical Nutrition ESPEN 2026, 72: 102914. PMID: 41520878, DOI: 10.1016/j.clnesp.2026.102914.
- Roessler N, Miszczyk M, Miyajima K, Dematteis A, Alfarhan A, Cormio A, Alqahtani A, Fazekas T, Schuettfort V, Vetterlein M, Hu Y, Kasivisvanathan V, Zamboglou C, Leapman M, Fisch M, Eckstein M, Amin M, Cacciamani G, Cheng L, Karakiewicz P, Rajwa P, Shariat S. Harnessing Artificial Intelligence for Risk Stratification and Outcome Prediction in Urologic Cancers: A Systematic Review. European Urology Focus 2025 PMID: 41412890, DOI: 10.1016/j.euf.2025.12.007.
- Diaz G, Sivanesan N, Strachan S, Sohoni N, DuBois J, Zhao X, Sprenkle P, Leapman M. Sociodemographic Factors Associated with Tissue-Based Genomic Testing for Prostate Cancer. Urology 2025 PMID: 41412501, DOI: 10.1016/j.urology.2025.12.004.
- Forman R, Westvold S, Long J, Fan J, Hyslop T, Conlin K, Jacobson S, Wang S, Leapman M, Cecchini M, Leeds I, Spees L, Presley C, Yasin F, Taylor M, Kwaramba T, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of frailty in long-term cancer survivors. Journal Of Geriatric Oncology 2025, 17: 102804. PMID: 41319472, DOI: 10.1016/j.jgo.2025.102804.
- Taylor M, Westvold S, Long J, Hyslop T, Silber A, Forman R, Yasin F, Kwaramba T, Wang S, Leapman M, Cecchini M, Leeds I, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Risk of Late-Onset Depression in Long-Term Survivors of Breast, Prostate, and Colorectal Cancer. JAMA Network Open 2025, 8: e2544812. PMID: 41296485, PMCID: PMC12658655, DOI: 10.1001/jamanetworkopen.2025.44812.
- Mitchell A, Salner A, Palyca P, Farooki A, Persaud S, Chakraborty N, Bhamidipati D, Klimchuk M, Dinan M, Leapman M, Lipitz-Snyderman A, Hamid A, Ostroff J, Morris M. Inter-Provider Variation in Initiation of Bone Modifying Agents for Patients with Prostate Cancer. JCO Oncology Practice 2025, op2500457-op2500457. PMID: 41183247, PMCID: PMC12614842, DOI: 10.1200/op-25-00457.
- Diaz G, Webb L, Lokeshwar S, Choksi A, Leapman M, Sprenkle P. Initial pain score during viscous lidocaine instillation and clinical characteristics as predictors of overall pain in fusion prostate biopsy. Journal Of Biological Methods 2025, 12: e99010077. PMID: 41415884, PMCID: PMC12709519, DOI: 10.14440/jbm.0230.
- Westvold S, Long J, Fan J, Kc M, Hyslop T, Conlin K, Jacobson S, Silber A, Wang S, Leapman M, Leeds I, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer. Journal Of The National Cancer Institute 2025, 118: 130-140. PMID: 41069232, DOI: 10.1093/jnci/djaf243.
- Kunst N, Long J, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation. JAMA Network Open 2025, 8: e2539250. PMID: 41134573, PMCID: PMC12552925, DOI: 10.1001/jamanetworkopen.2025.39250.
- Baum L, Soulos P, Kc M, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Liberatore M, Leapman M, Jairam V, Dinan M, Gross C, Park H. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Cancer 2025, 131: e70027. PMID: 40977160, PMCID: PMC12451255, DOI: 10.1002/cncr.70027.
- Palencia P, Smani S, Zhao X, Kandala K, Sivanesan N, Cavallo J, Roessler N, Aneja S, An Y, Miszczyk M, Leapman M. Association between prostate radiotherapy and survival among patients with metastatic prostate cancer by extent of disease burden. Radiotherapy And Oncology 2025, 213: 111158. PMID: 40987387, DOI: 10.1016/j.radonc.2025.111158.
- Sivanesan N, Diaz G, Strachan S, Kandala K, Zhao X, Tan W, Leapman M, Sprenkle P. MRI-fusion biopsy era: the role of perineural invasion in low-risk prostate cancer. Current Problems In Cancer 2025, 59: 101251. PMID: 40946534, DOI: 10.1016/j.currproblcancer.2025.101251.
- Rabil M, Choksi A, Leapman M. Harmonizing environmental and economic forces in urologic care. Current Opinion In Urology 2025, 35: 679-684. PMID: 40948360, DOI: 10.1097/mou.0000000000001338.
- Roessler N, Miszczyk M, Matsukawa A, Dematteis A, Alfarhan A, Cormio A, Alqahtani A, Rajwa P, Schuettfort V, Vetterlein M, Soeterik T, Fazekas T, Fisch M, Leapman M, Karakiewicz P, Shariat S. Impact of PARP Inhibitors on Health-related Quality of Life in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Open Science 2025, 80: 48-56. PMID: 40994543, PMCID: PMC12454867, DOI: 10.1016/j.euros.2025.08.008.
- Rabil M, Jalfon M, Palencia P, Heckscher D, Kong V, Golos A, Richmond R, Chess A, Kim I, Leapman M, Cavallo J. Automated electronic medical record abstraction algorithm for radical prostatectomy outcomes. Urologic Oncology Seminars And Original Investigations 2025, 43: 710.e1-710.e8. PMID: 40885622, DOI: 10.1016/j.urolonc.2025.07.028.
- Ward B, Zhang A, Leapman M, Cavallo J, Kim I. Early Continence and Erectile Function Recovery Following Transvesical Single-Port Robot-Assisted Radical Prostatectomy: Initial Single Institution Experience. Cancers 2025, 17: 2793. PMID: 40940891, PMCID: PMC12427196, DOI: 10.3390/cancers17172793.
- Makarov D, Thomas J, Ciprut S, Rivera A, Sherman S, Braithwaite R, Best S, Blakely S, D’Agostino L, Dahm P, Dash A, Leapman M, Leppert J, Sanchez A, Shelton J, Tessier C, Tenner C, Gold H, Shedlin M, Zeliadt S. Prostate Cancer Imaging Stewardship: a multimodal, physician-centered intervention for guideline-concordant imaging. Journal Of The National Cancer Institute 2025, 117: 2308-2316. PMID: 40796156, DOI: 10.1093/jnci/djaf210.
- Zurl H, Korn S, Pohl K, Qian Z, Piccolini A, Iyer H, Leapman M, Ahyai S, Shariat S, Trinh Q, Thiel C, Loeb S, Cole A. Estimating the Carbon Emissions of a Single Prostate-specific Antigen Test: Results from a Cradle-to-grave Life Cycle Assessment. European Urology Focus 2025, 11: 1023-1031. PMID: 40753028, DOI: 10.1016/j.euf.2025.07.006.
- Smani S, Wang R, Zhou X, Sprenkle P, Kim I, Dinan M, Gross C, Ma X, Leapman M. Area-Level Social Deprivation and Use of Prostate MRI Before Prostate Biopsy Among Commercial Insurance Beneficiaries. Urology 2025, 205: 145-151. PMID: 40759400, DOI: 10.1016/j.urology.2025.07.070.
- Smani S, Lokeshwar S, Jalfon M, Heckscher D, Press B, Heacock D, Leapman M, Kenney P, Ghali F. Development and Utilization of a Novel Electronic Health Record–Based Care Pathway for Nonmuscle-Invasive Bladder Cancer. Urology Practice 2025, 12: 628-631. PMID: 40637707, DOI: 10.1097/upj.0000000000000872.
- Roessler N, Miszczyk M, Dematteis A, Zattoni F, Fazekas T, Carletti F, Reitano G, Matsukawa A, Alfarhan A, Cormio A, Alqahtani A, Soeterik T, Marvaso G, Gandaglia G, Nyirády P, Rajwa P, Nyk Ł, Palencia P, Leapman M, Jereczek-Fossa B, Shariat S. Prostate radiotherapy in patients with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis of randomised controlled trials. Clinical And Translational Radiation Oncology 2025, 54: 101009. PMID: 40687731, PMCID: PMC12272608, DOI: 10.1016/j.ctro.2025.101009.
- Sundaresan V, Leapman M. Debate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate Cancer. Seminars In Radiation Oncology 2025, 35: 385-392. PMID: 40516973, DOI: 10.1016/j.semradonc.2025.05.001.
- Miszczyk M, Fazekas T, Rajwa P, Matsukawa A, Tsuboi I, Leapman M, Kramer G, Hussain M, Merseburger A, Briganti A, D'Amico A, Gillessen S, Saad F, Shariat S. Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis. European Urology Focus 2025, 11: 755-766. PMID: 40379533, DOI: 10.1016/j.euf.2025.03.019.
- Buck M, Smani S, Nguyen J, Abello A, Jalfon M, Lokeshwar S, Leapman M, Cavallo J, Kenney P. Antibiotic prophylaxis prior to office-based urologic procedures: outcomes from a department-wide quality improvement project. World Journal Of Urology 2025, 43: 257. PMID: 40299076, DOI: 10.1007/s00345-025-05642-0.
- Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Kunst N, Wang S, Ma X, Gross C, Leapman M, Karnes R. Prostate-Specific Membrane Antigen Imaging Findings and Subsequent Clinical Management Among Patients With Biochemically Recurrent Prostate Cancer. JU Open Plus 2025, 3 DOI: 10.1097/ju9.0000000000000278.
- Diaz G, Palencia P, Leapman M. Delivering on the Promise of Precision Oncology in Prostate Cancer: Prediagnostic Strategies, Postdiagnostic Applications, and Future Directions. A Narrative Review. Journal Of Urologic Oncology 2025, 23: 4-13. DOI: 10.22465/juo.255000120006.
- Khajir G, Webb L, Lokeshwar S, Diaz G, Anderson T, Choksi A, Zhao J, Leapman M, Sprenkle P, Renzulli J. Diagnostic performance of high-resolution micro-ultrasound and conventional ultrasound in fusion biopsy for clinically significant prostate cancer detection. Urologic Oncology Seminars And Original Investigations 2025, 43: 399.e1-399.e8. PMID: 40121104, DOI: 10.1016/j.urolonc.2025.03.006.
- McManus H, Long J, Westvold S, Leapman M, Hurwitz M, Mitchell A, Pollack C, Gross C, Dinan M. Off-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2025, 23: 102330. PMID: 40186898, PMCID: PMC12084128, DOI: 10.1016/j.clgc.2025.102330.
- Miszczyk M, Stando R, Francolini G, Zamboglou C, Cadenar A, Suleja A, Fazekas T, Matsukawa A, Tsuboi I, Przydacz M, Leapman M, Rajwa P, Supiot S, Shariat S. Perirectal spacers in radiotherapy for prostate cancer – a systematic review and meta-analysis. Współczesna Onkologia 2025, 29: 36-44. PMID: 40330445, PMCID: PMC12051878, DOI: 10.5114/wo.2025.148388.
- Chen F, Esmaili R, Khajir G, Zeevi T, Gross M, Leapman M, Sprenkle P, Justice A, Arora S, Weinreb J, Spektor M, Huber S, Humphrey P, Levi A, Staib L, Venkataraman R, Martin D, Onofrey J. Comparative Performance of Machine Learning Models in Reducing Unnecessary Targeted Prostate Biopsies. European Urology Oncology 2025, 9: 142-149. PMID: 39924390, PMCID: PMC12332026, DOI: 10.1016/j.euo.2025.01.005.
- Cole A, Qian Z, Gupta N, Leapman M, Zurl H, Trinh Q, Sherman J, Loeb S, Iyer H. Urology on a changing planet: links between climate change and urological disease. Nature Reviews Urology 2025, 22: 208-222. PMID: 39875561, DOI: 10.1038/s41585-024-00979-4.
- Kim I, Leapman M, Kim M, Rahman S, Sprenkle P, Renzulli J, Brito J, Hyams E, Kim J, Pareek G, Kim I. Radical prostatectomy is associated with favorable outcomes in patients over 80 years old. American Journal Of Clinical And Experimental Urology 2025, 13: 33-42. PMID: 40124572, PMCID: PMC11928824, DOI: 10.62347/nkgs2301.
- Ajjawi I, Smani S, Kandala K, Sohoni N, Sutherland R, Washington S, Kim I, Leapman M. Factors associated with time to prostate cancer treatment initiation during the COVID-19 pandemic. American Journal Of Clinical And Experimental Urology 2025, 13: 306-315. PMID: 40978091, PMCID: PMC12444389, DOI: 10.62347/binh7737.
- Sundaresan V, Webb L, Rabil M, Golos A, Sutherland R, Bailey J, Rajwa P, Seibert T, Loeb S, Cooperberg M, Catalona W, Sprenkle P, Kim I, Leapman M. Risks of grade reclassification among patients with Gleason grade group 1 prostate cancer and PI-RADS 5 findings on prostate MRI. Urologic Oncology Seminars And Original Investigations 2024, 43: 193.e19-193.e26. PMID: 39706698, DOI: 10.1016/j.urolonc.2024.11.007.
- Ajjawi I, Loeb S, Cooperberg M, Catalona W, Gross C, Ma X, Leapman M. Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020. JAMA: The Journal Of The American Medical Association 2024, 332: 2033-2036. PMID: 39565605, PMCID: PMC11579888, DOI: 10.1001/jama.2024.20580.
- Sigel K, Yu R, Chiao E, Deshmukh A, Leapman M. Prostate cancer in people with HIV. Current Opinion In Infectious Diseases 2024, 38: 10-17. PMID: 39624951, PMCID: PMC11695140, DOI: 10.1097/qco.0000000000001076.
- Lokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Sutherland R, Brito J, Renzulli J, Sprenkle P, Leapman M. Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy. Urologic Oncology Seminars And Original Investigations 2024, 43: 336.e13-336.e20. PMID: 39521675, DOI: 10.1016/j.urolonc.2024.10.018.
- Marks V, Williams B, Leapman M, Shields C. The Association Between Medical Insurance, Access to Care, and Outcomes for Patients with Uveal Melanoma in the United States. Seminars In Ophthalmology 2024, 40: 223-234. PMID: 39520301, DOI: 10.1080/08820538.2024.2426479.
- Rahman S, Kim H, Webb L, Diaz G, Leapman M, Sprenkle P, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2024, 0: 0-0. PMID: 39697737, PMCID: PMC11651831, DOI: 10.21037/tcr-24-245.
- Washington S, Fakunle M, Wang L, Braun A, Leapman M, Cowan J, Cooperberg M. County-level racial disparities in prostate cancer–specific mortality from 2005 to 2020. JNCI Cancer Spectrum 2024, 8: pkae109. PMID: 39495143, PMCID: PMC11631307, DOI: 10.1093/jncics/pkae109.
- Gaylis F, Leapman M, Ellis S, Hu S, Cooperberg M, Loeb S, Chen R, Cohen E, Dato P, Aynehchi S, David R, Topp R, Santomauro B, Ginsburg K, Catalona W. Feasibility of Pay for Performance and Transparency Interventions on the Selection and Quality of Observational Management for Patients With Low-Risk Prostate Cancer in the Community Practice. Urology Practice 2024, 12: 241-248. PMID: 39453985, DOI: 10.1097/upj.0000000000000745.
- Smani S, Jalfon M, Sundaresan V, Lokeshwar S, Nguyen J, Halstuch D, Khajir G, Cavallo J, Sprenkle P, Leapman M, Kim I. Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? Urologic Oncology Seminars And Original Investigations 2024, 43: 396.e1-396.e7. PMID: 39438211, DOI: 10.1016/j.urolonc.2024.10.002.
- Fazekas T, Pallauf M, Kufel J, Miszczyk M, Tsuboi I, Matsukawa A, Laukhtina E, Kardoust Parizi M, Mancon S, Cadenar A, Schulz R, Yanagisawa T, Baboudjian M, Szarvas T, Gandaglia G, Tilki D, Nyirády P, Rajwa P, Leapman M, Shariat S. Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review. European Urology Oncology 2024, 8: 1352-1364. PMID: 39414421, DOI: 10.1016/j.euo.2024.09.017.
- Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, PMCID: PMC11581571, DOI: 10.1001/jamanetworkopen.2024.40591.
- Sundaresan V, Lokeshwar S, Sutherland R, Sohoni N, Golos A, Ajjawi I, Leapman M. Sociodemographic disparities in prostate cancer imaging. Abdominal Radiology 2024, 51: 1407-1415. PMID: 39325212, DOI: 10.1007/s00261-024-04603-2.
- Press B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, Sprenkle P. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. PMID: 39465014, PMCID: PMC11502073, DOI: 10.37349/etat.2024.00269.
- Rabil M, Leapman M, Cavallo J. Reply to Editorial Comment on “Association of Crowd-Sourced Assessment of Technical Skills and Outcomes of Robotic-assisted Radical Prostatectomy”. Urology 2024, 193: 97-98. PMID: 39208938, DOI: 10.1016/j.urology.2024.08.054.
- Forman R, Long J, Westvold S, Agnish K, McManus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, 8: pkae067. PMID: 39133171, PMCID: PMC11376369, DOI: 10.1093/jncics/pkae067.
- Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024, 8: 1101-1110. PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.
- Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. PMID: 39280242, PMCID: PMC11390291, DOI: 10.37349/etat.2024.00259.
- Sundaresan V, Smani S, Rajwa P, Renzulli J, Sprenkle P, Kim I, Leapman M. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urologic Oncology Seminars And Original Investigations 2024, 43: 41-48. PMID: 39019723, DOI: 10.1016/j.urolonc.2024.06.003.
- Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 11: 965-973. PMID: 39196719, PMCID: PMC12400587, DOI: 10.1097/upj.0000000000000679.
- Rabil M, Jalfon M, Heckscher D, Song Z, Li F, Martin T, Sprenkle P, Hesse D, Kim I, Leapman M, Cavallo J. Association of Crowd-Sourced Assessment of Technical Skills and Outcomes of Robotic-assisted Radical Prostatectomy. Urology 2024, 193: 87-94. PMID: 39019332, DOI: 10.1016/j.urology.2024.07.014.
- Lokeshwar S, Choksi A, Smani S, Ip K, Javier-DesLoges J, Rahman S, Leapman M, Martin T, Hesse D. Classification and Risk Factors for Surgical Site Infections in Radical Cystectomy: A 16-Year Analysis. Surgical Infections 2024, 25: 580-585. PMID: 38959160, PMCID: PMC11807858, DOI: 10.1089/sur.2024.107.
- Diaz G, Webb L, Rabil M, Lokeshwar S, Choksi A, Leapman M, Sprenkle P. Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. Current Urology Reports 2024, 25: 243-252. PMID: 38896314, DOI: 10.1007/s11934-024-01220-w.
- Demkowicz P, Buck M, Nie J, Marks V, Wheeler S, Dinan M, Gross C, Leapman M. Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act. Urology 2024, 192: 19-27. PMID: 38901803, DOI: 10.1016/j.urology.2024.06.003.
- Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.
- Fazekas T, Shim S, Basile G, Baboudjian M, Kói T, Przydacz M, Abufaraj M, Ploussard G, Kasivisvanathan V, Rivas J, Gandaglia G, Szarvas T, Schoots I, van den Bergh R, Leapman M, Nyirády P, Shariat S, Rajwa P. Magnetic Resonance Imaging in Prostate Cancer Screening. JAMA Oncology 2024, 10: 745-754. PMID: 38576242, PMCID: PMC10998247, DOI: 10.1001/jamaoncol.2024.0734.
- Lokeshwar S, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Mehal W, Brito J, Renzulli J, Leapman M. The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy. BMC Urology 2024, 24: 102. PMID: 38702664, PMCID: PMC11067086, DOI: 10.1186/s12894-024-01483-y.
- Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Ellis S, Loeb S, Schulman‐Green D, Leapman M. ‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer. BJUI Compass 2024, 5: 707-715. PMID: 38873351, PMCID: PMC11168777, DOI: 10.1002/bco2.351.
- Rahman S, Long J, Westvold S, Leapman M, Spees L, Hurwitz M, McManus H, Gross C, Wheeler S, Dinan M. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2024, 7: e248747. PMID: 38687479, PMCID: PMC11061765, DOI: 10.1001/jamanetworkopen.2024.8747.
- Zeevi T, Leapman M, Sprenkle P, Venkataraman R, Staib L, Onofrey J. Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy Histopathology. IEEE Transactions On Biomedical Engineering 2024, 71: 1084-1091. PMID: 37874731, PMCID: PMC10901528, DOI: 10.1109/tbme.2023.3326799.
- Kim I, Wang A, Corpuz G, Sprenkle P, Leapman M, Brito J, Renzulli J, Kim I. Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy. Prostate International 2024, 12: 70-78. PMID: 39036758, PMCID: PMC11255894, DOI: 10.1016/j.prnil.2024.01.002.
- Justice A, Tate J, Howland F, Gaziano J, Kelley M, McMahon B, Haiman C, Wadia R, Madduri R, Danciu I, Leppert J, Leapman M, Thurtle D, Gnanapragasam V. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer. European Urology Oncology 2024, 7: 923-932. PMID: 38171965, DOI: 10.1016/j.euo.2023.11.023.
- Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco J, Washington S, Renzulli J, Sprenkle P, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urologic Oncology Seminars And Original Investigations 2023, 42: 28.e9-28.e20. PMID: 38161105, DOI: 10.1016/j.urolonc.2023.10.005.
- Marks V, Hsiang W, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar M, Pantel H, Berger E, Boffa D, Cavallo J, Leapman M. Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study. JMIR Cancer 2023, 9: e45518. PMID: 37917149, PMCID: PMC10654905, DOI: 10.2196/45518.
- Heckscher D, Jalfon M, Buck M, Abello A, Nguyen J, Casilla-Lennon M, Leapman M, Hittelman A, Teitelbaum J, Emerson B, Kenney P, Cavallo J, Lambert S. Implementation of a health system intervention to reduce time from presentation to surgical intervention for pediatric testicular torsion. Journal Of Pediatric Urology 2023, 20: 254.e1-254.e7. PMID: 38030428, DOI: 10.1016/j.jpurol.2023.10.042.
- Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.
- Baum L, KC M, Soulos P, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Trends in new and persistent opioid use in older adults with and without cancer. Journal Of The National Cancer Institute 2023, 116: 316-323. PMID: 37802882, PMCID: PMC13032033, DOI: 10.1093/jnci/djad206.
- Leapman M. Embracing Challenges and Opportunities Posed by New Technologies in Urologic Care. Urology Practice 2023, 11: 7-8. PMID: 37747948, DOI: 10.1097/upj.0000000000000459.
- Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancerLeapman M, Sutherland R, Gross C, Ma X, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman‐Green D. Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer. BJUI Compass 2023, 5: 142-149. PMID: 38179031, PMCID: PMC10764160, DOI: 10.1002/bco2.277.
- Ślusarczyk A, Baboudjian M, Zapała P, Yanagisawa T, Miszczyk M, Chlosta M, Krumpoeck P, Moschini M, Gandaglia G, Ploussard G, Rivas J, Życzkowski M, Karakiewicz P, Radziszewski P, Leapman M, Shariat S, Rajwa P. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations. The Prostate 2023, 83: 1504-1515. PMID: 37545342, DOI: 10.1002/pros.24609.
- Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.
- Jalfon M, Sakhalkar O, Lokeshwar S, Marks V, Choksi A, Klaassen Z, Leapman M, Kim I. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer. Current Urology Reports 2023, 24: 455-461. PMID: 37369828, DOI: 10.1007/s11934-023-01173-6.
- Lokeshwar S, Choksi A, Haltstuch D, Rahman S, Press B, Syed J, Hurwitz M, Kim I, Leapman M. Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics. World Journal Of Urology 2023, 41: 2007-2019. PMID: 37160450, DOI: 10.1007/s00345-023-04409-9.
- Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum 2023, 7: pkad036. PMID: 37202354, PMCID: PMC10276895, DOI: 10.1093/jncics/pkad036.
- Leapman M, Loeb S, Cooperberg M, Catalona W, Gaylis F. A vision for closing the evidence-practice gap in the management of low-grade prostate cancer. JNCI Cancer Spectrum 2023, 7: pkad028. PMID: 37101361, PMCID: PMC10133397, DOI: 10.1093/jncics/pkad028.
- Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.
- Laditi F, Nie J, Hsiang W, Umer W, Haleem A, Marks V, Buck M, Leapman M. Access to urologic cancer care for Medicaid-insured patients. Urologic Oncology Seminars And Original Investigations 2023, 41: 206.e21-206.e27. PMID: 36740488, DOI: 10.1016/j.urolonc.2023.01.014.
- Leapman M, Thiel C, Gordon I, Nolte A, Perecman A, Loeb S, Overcash M, Sherman J. Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy. European Urology 2023, 83: 463-471. PMID: 36635108, DOI: 10.1016/j.eururo.2022.12.008.
- Chu C, Leapman M, Zhao S, Cowan J, Washington S, Cooperberg M. Prostate cancer disparities among American Indians and Alaskan Natives in the United States. Journal Of The National Cancer Institute 2023, 115: 413-420. PMID: 36629492, PMCID: PMC10086629, DOI: 10.1093/jnci/djad002.
- Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman M, Gore J, Paradysz A, Tilki D, Merseburger A, Morgan T, Briganti A, Palapattu G, Shariat S. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology 2023, 20: 205-216. PMID: 36600087, DOI: 10.1038/s41585-022-00680-4.
- Rahman S, Lokeshwar S, Syed J, Javier-Desloges J, Press B, Choksi A, Rajwa P, Pradere B, Ploussard G, Kim J, Monaghan T, Renzulli J, Shariat S, Leapman M. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. Urologic Oncology Seminars And Original Investigations 2022, 41: 107.e1-107.e8. PMID: 36481253, DOI: 10.1016/j.urolonc.2022.09.008.
- Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncology Practice 2022, 19: e213-e227. PMID: 36413741, PMCID: PMC9970274, DOI: 10.1200/op.22.00401.
- Nabavizadeh B, Li KD, Hakam N, Shaw NM, Leapman MS, Breyer BN. Incidence of circumcision among insured adults in the United States. PLOS ONE 2022, 17: e0275207. PMID: 36251658, PMCID: PMC9576047, DOI: 10.1371/journal.pone.0275207.
- Marks VA, Hsiang WR, Nie J, Demkowicz P, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar MC, Berger ER, Boffa DJ, Leapman MS. Acceptance of Simulated Adult Patients With Medicaid Insurance Seeking Care in a Cancer Hospital for a New Cancer Diagnosis. JAMA Network Open 2022, 5: e2222214. PMID: 35838668, PMCID: PMC9287756, DOI: 10.1001/jamanetworkopen.2022.22214.
- Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.
- Holler J, Hakam N, Nabavizadeh B, Sadighian M, Shibley W, Li K, Weiser L, Rios N, Enriquez A, Leapman M, Amend G, Breyer B. Characteristics of Online Crowdfunding Campaigns for Urological Cancers in the United States. Urology Practice 2021, 9: 56-63. PMID: 37145560, PMCID: PMC12721642, DOI: 10.1097/upj.0000000000000275.
- Nie J, Demkowicz P, Hsiang W, Umer W, Chen E, McMahon G, Kenney P, Breyer B, Parikh R, Leapman M. Urology Practice Acquisitions by Private Equity Firms from 2011–2021. Urology Practice 2021, 9: 17-24. PMID: 37145557, DOI: 10.1097/upj.0000000000000269.
- Nie J, Demkowicz P, Hsiang W, Umer W, Chen E, McMahon G, Kenney P, Breyer B, Parikh R, Leapman M. Reply by Authors. Urology Practice 2021, 9: 24-24. PMID: 37145588, DOI: 10.1097/upj.0000000000000269.02.
- Advani S, Gao C, Datta R, Sann L, Smith C, Leapman MS, Hittelman A, Sabetta J, Dembry LM, Martinello RA, Juthani-Mehta M. Knowledge and Practices of Physicians and Nurses related to Urine Cultures in Catheterized Patients: An Assessment of Adherence to IDSA Guidelines. Open Forum Infectious Diseases 2019, 6: ofz305. PMID: 31375836, PMCID: PMC6677670, DOI: 10.1093/ofid/ofz305.
- Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate CancerLeapman MS, Wang R, Park HS, Yu JB, Weinreb JC, Gross CP, Ma X. Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. Urology 2018, 124: 98-106. PMID: 30107188, DOI: 10.1016/j.urology.2018.07.041.
- Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll PR. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PLOS ONE 2017, 12: e0185535. PMID: 29016610, PMCID: PMC5634556, DOI: 10.1371/journal.pone.0185535.
- Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR. Active Surveillance in Younger Men With Prostate Cancer. Journal Of Clinical Oncology 2017, 35: jco.2016.68.005. PMID: 28346806, PMCID: PMC5466007, DOI: 10.1200/jco.2016.68.0058.
- Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer OutcomesLeapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. European Urology 2016, 71: 750-759. PMID: 27940155, DOI: 10.1016/j.eururo.2016.11.032.
- Leapman M, Carroll P. Risk Stratification of Newly Diagnosed Prostate Cancer with Genomic Platforms. Urology Practice 2016, 4: 322-328. PMID: 37592678, DOI: 10.1016/j.urpr.2016.06.008.
- Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal Of Urology 2016, 196: 1408-1414. PMID: 27352635, PMCID: PMC5542578, DOI: 10.1016/j.juro.2016.06.086.
- Leapman M, Shinohara K. TRUS Biopsy: Is There Still a Role? 2016, 53-67. DOI: 10.1007/978-3-319-21485-6_4.
- Leapman M, Cooperberg M. Clinical Risk Prediction Tools for Prostate Cancer: TNM to CAPRA—Should Risk Be Redefined? 2016, 33-52. DOI: 10.1007/978-3-319-21485-6_3.
- Polland A, Leapman M, Stone N. A Case-Based Illustration of Urinary Symptoms Following Radiation Therapy for Prostate Cancer. 2015, 151-172. DOI: 10.1007/978-3-319-23817-3_11.
- Leapman M, Stone N. Urinary Retention and Incontinence after Low-Dose-Rate Brachytherapy for Prostate Cancer. Current Bladder Dysfunction Reports 2013, 8: 236-241. DOI: 10.1007/s11884-013-0188-5.
- Yale UrologyYale Physicians Building800 Howard AvenueNew Haven, CT 06519
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
Biography
Michael S. Leapman, MD, who specializes in prostate, bladder, testicular and kidney cancers, loves his work as a urologic oncologist.
“Every day, I have the ability to make a difference in a patient's life,” says Dr. Leapman. “It's a tremendous honor and responsibility, and it's very rewarding.”
A member of Yale Cancer Center, he sees patients at Smilow Cancer Hospital and the West Haven Veteran’s Administration. An assistant professor of urology at Yale School of Medicine, he studies the best treatments for prostate cancer and how gene expression signatures can predict the aggressiveness of this cancer.
“Hearing the emotionally wrought words ‘it’s cancer’ is extremely difficult to navigate,” he says. “So that's one of the issues that we are sensitive to, and continue to strive to improve.”
The patient-physician bond is essential in helping patients with prostate cancer, for example, to choose which kind of treatment is best: surgery, radiation therapy or active surveillance, an ongoing monitoring of what can be a slow-progressing disease.
“It really is a very special relationship between a urologist and a patient. I have found that the team at Yale is 100 percent invested in the outcomes of our patients, and we stand out by seeking to understand their concerns, goals by being there for them every step of the way.”
Titles
- Associate Professor of Urology
- Clinical Program Leader, Prostate & Urologic Cancers Program, Yale Cancer Center
- Assistant Professor, Chronic Disease Epidemiology
Education & Training
- MHSYale University (2022)
- FellowshipUniversity of California San Francisco (2016)
- ResidencyMount Sinai Medical Center (2014)
- InternshipMount Sinai Medical Center (2010)
- MDUniversity of Maryland School of Medicine (2009)
- BACornell University (2005)
Additional Information
- John N. Forrest Jr. Prize for Mentorship in Student Research: (2022)
- Best Poster: European School of Oncology, Conference on Active Surveillance (2016)
- Merit Award: Conquer Cancer Foundation of the American Society of Clinical Oncology (2015)
- First Place Essay, History Section: American Urological Association Western Section (2015)
- Joseph F. McCarthy Physician Essay Contest, Third Place: American Urological Association Western Section (2015)
- Outstanding Abstract Selected for Oral Presentation: University of California San Francisco (2015)
- Resident Publication Award: Mount Sinai Medical Center, Department of Urology (2014)
- Resident Travel Award: Society for Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (2013)
- AB of Urology, Urology (2018)
- Leapman M, Rothen J, Long J, Kim I, Mitchell A, Yu J, Dinan M, Gross C, Ma X. Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer. JAMA Oncology 2026, 12 PMID: 42096231, PMCID: PMC13154023, DOI: 10.1001/jamaoncol.2026.0893.
- Palencia P, Xi X, Zhao X, Ward B, Smani S, Sivanesan N, Diaz G, Miszczyk M, Fazekas T, Rajwa P, Cavallo J, Aneja S, An Y, Kim I, Leapman M. Association Between Perirectal Spacer Use and Short-Term Complications Following Prostate Radiation Therapy in a National Claims Based Analysis. Urology Practice 2026, 101097upj0000000000000996. PMID: 41810984, DOI: 10.1097/upj.0000000000000996.
- Ajjawi I, Kim I, Smani S, Palencia P, Diaz G, Lee W, Kim I, Sprenkle P, Leapman M. Machine learning approaches to optimize the integration of sociodemographic factors for predicting cancer-specific survival among patients with high-risk prostate cancer. Current Urology 2026 DOI: 10.1097/cu9.0000000000000335.
- Lim D, Cavallo J, Leapman M, Ghodoussipour S, Kim I. Comprehensive Outcome Analysis of Single-Port Robot-Assisted Radical Prostatectomy. Journal Of Endourology 2026, 40: 321-327. PMID: 41314953, DOI: 10.1177/08927790251400364.
- Ajjawi I, Sprenkle P, Renzulli J, Leapman M. Re-evaluating the Role of Locoregional Therapy in Metastatic Prostate Cancer: A Review of Current Evidence and Evolving Clinical Approaches. Urologic Clinics Of North America 2026 DOI: 10.1016/j.ucl.2026.02.002.
- Miszczyk M, Sohoni N, Smani S, Moll M, Alfarhan A, Roessler N, Miyajima K, Inoue S, Marvaso G, Mastroleo F, Zamboglou C, Soeterik T, Zilli T, Terlizzi M, Blanchard P, Rajwa P, Fazekas T, Ploussard G, An Y, Leapman M, Blanck O, Jereczek-Fossa B, Shariat S. Efficacy and tolerability of hypofractionated and dose-boosted radiotherapy for localised prostate cancer: a systematic review and meta-analysis. Radiotherapy And Oncology 2026, 218: 111445. PMID: 41713502, DOI: 10.1016/j.radonc.2026.111445.
- Smani S, Sohoni N, Miszczyk M, Fazekas T, Rajwa P, Grimshaw A, Sundaresan V, Lokeshwar S, Weinreb J, Sprenkle P, Cooperberg M, Seibert T, Shariat S, Catalona W, Leapman M. Association between baseline prostate MRI PI-RADS classification and risk of Gleason upgrade during active surveillance: a systematic review and meta-analysis. World Journal Of Urology 2026, 44: 169. PMID: 41691567, DOI: 10.1007/s00345-026-06278-4.
- Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Spilberg G, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Rivera D, Kluetz P, Karnes R, Dinan M, Mitchell A, Kunst N, Wang S, Ma X, Gross C. Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States. JCO Oncology Practice 2026, op2500617. PMID: 41632928, DOI: 10.1200/op-25-00617.
- Kim I, Puri D, Rathi N, Leapman M, Kim I. Lack of survival benefit of pelvic lymph node dissection for patients with radical prostatectomy and postprostatectomy radiotherapy. Urologic Oncology Seminars And Original Investigations 2026, 44: 110985. PMID: 41576629, DOI: 10.1016/j.urolonc.2025.110985.
- Sohoni N, Sohoni N, Sutherland R, Sundaresan V, Smani S, Ananth P, Onofrey J, Aneja S, Miszczyk M, Lee H, Olivieri J, Leapman M. Automated Classification of Adverse Events After Hydrogel Perirectal Spacer Insertion for Prostate Cancer Using Large Language Models. Urology 2026, 209: 18-24. PMID: 41565161, DOI: 10.1016/j.urology.2026.01.008.
- Souroujon Torun A, Sundaresan V, Golos A, Leapman M, Gomez-Santamaría O, Casilla-Lennon M. The role of nutrition in prostate cancer risk, progression, and mortality: A comprehensive review. Clinical Nutrition ESPEN 2026, 72: 102914. PMID: 41520878, DOI: 10.1016/j.clnesp.2026.102914.
- Roessler N, Miszczyk M, Miyajima K, Dematteis A, Alfarhan A, Cormio A, Alqahtani A, Fazekas T, Schuettfort V, Vetterlein M, Hu Y, Kasivisvanathan V, Zamboglou C, Leapman M, Fisch M, Eckstein M, Amin M, Cacciamani G, Cheng L, Karakiewicz P, Rajwa P, Shariat S. Harnessing Artificial Intelligence for Risk Stratification and Outcome Prediction in Urologic Cancers: A Systematic Review. European Urology Focus 2025 PMID: 41412890, DOI: 10.1016/j.euf.2025.12.007.
- Diaz G, Sivanesan N, Strachan S, Sohoni N, DuBois J, Zhao X, Sprenkle P, Leapman M. Sociodemographic Factors Associated with Tissue-Based Genomic Testing for Prostate Cancer. Urology 2025 PMID: 41412501, DOI: 10.1016/j.urology.2025.12.004.
- Forman R, Westvold S, Long J, Fan J, Hyslop T, Conlin K, Jacobson S, Wang S, Leapman M, Cecchini M, Leeds I, Spees L, Presley C, Yasin F, Taylor M, Kwaramba T, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of frailty in long-term cancer survivors. Journal Of Geriatric Oncology 2025, 17: 102804. PMID: 41319472, DOI: 10.1016/j.jgo.2025.102804.
- Taylor M, Westvold S, Long J, Hyslop T, Silber A, Forman R, Yasin F, Kwaramba T, Wang S, Leapman M, Cecchini M, Leeds I, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Risk of Late-Onset Depression in Long-Term Survivors of Breast, Prostate, and Colorectal Cancer. JAMA Network Open 2025, 8: e2544812. PMID: 41296485, PMCID: PMC12658655, DOI: 10.1001/jamanetworkopen.2025.44812.
- Mitchell A, Salner A, Palyca P, Farooki A, Persaud S, Chakraborty N, Bhamidipati D, Klimchuk M, Dinan M, Leapman M, Lipitz-Snyderman A, Hamid A, Ostroff J, Morris M. Inter-Provider Variation in Initiation of Bone Modifying Agents for Patients with Prostate Cancer. JCO Oncology Practice 2025, op2500457-op2500457. PMID: 41183247, PMCID: PMC12614842, DOI: 10.1200/op-25-00457.
- Diaz G, Webb L, Lokeshwar S, Choksi A, Leapman M, Sprenkle P. Initial pain score during viscous lidocaine instillation and clinical characteristics as predictors of overall pain in fusion prostate biopsy. Journal Of Biological Methods 2025, 12: e99010077. PMID: 41415884, PMCID: PMC12709519, DOI: 10.14440/jbm.0230.
- Westvold S, Long J, Fan J, Kc M, Hyslop T, Conlin K, Jacobson S, Silber A, Wang S, Leapman M, Leeds I, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer. Journal Of The National Cancer Institute 2025, 118: 130-140. PMID: 41069232, DOI: 10.1093/jnci/djaf243.
- Kunst N, Long J, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation. JAMA Network Open 2025, 8: e2539250. PMID: 41134573, PMCID: PMC12552925, DOI: 10.1001/jamanetworkopen.2025.39250.
- Baum L, Soulos P, Kc M, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Liberatore M, Leapman M, Jairam V, Dinan M, Gross C, Park H. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Cancer 2025, 131: e70027. PMID: 40977160, PMCID: PMC12451255, DOI: 10.1002/cncr.70027.
- Palencia P, Smani S, Zhao X, Kandala K, Sivanesan N, Cavallo J, Roessler N, Aneja S, An Y, Miszczyk M, Leapman M. Association between prostate radiotherapy and survival among patients with metastatic prostate cancer by extent of disease burden. Radiotherapy And Oncology 2025, 213: 111158. PMID: 40987387, DOI: 10.1016/j.radonc.2025.111158.
- Sivanesan N, Diaz G, Strachan S, Kandala K, Zhao X, Tan W, Leapman M, Sprenkle P. MRI-fusion biopsy era: the role of perineural invasion in low-risk prostate cancer. Current Problems In Cancer 2025, 59: 101251. PMID: 40946534, DOI: 10.1016/j.currproblcancer.2025.101251.
- Rabil M, Choksi A, Leapman M. Harmonizing environmental and economic forces in urologic care. Current Opinion In Urology 2025, 35: 679-684. PMID: 40948360, DOI: 10.1097/mou.0000000000001338.
- Roessler N, Miszczyk M, Matsukawa A, Dematteis A, Alfarhan A, Cormio A, Alqahtani A, Rajwa P, Schuettfort V, Vetterlein M, Soeterik T, Fazekas T, Fisch M, Leapman M, Karakiewicz P, Shariat S. Impact of PARP Inhibitors on Health-related Quality of Life in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Open Science 2025, 80: 48-56. PMID: 40994543, PMCID: PMC12454867, DOI: 10.1016/j.euros.2025.08.008.
- Rabil M, Jalfon M, Palencia P, Heckscher D, Kong V, Golos A, Richmond R, Chess A, Kim I, Leapman M, Cavallo J. Automated electronic medical record abstraction algorithm for radical prostatectomy outcomes. Urologic Oncology Seminars And Original Investigations 2025, 43: 710.e1-710.e8. PMID: 40885622, DOI: 10.1016/j.urolonc.2025.07.028.
- Ward B, Zhang A, Leapman M, Cavallo J, Kim I. Early Continence and Erectile Function Recovery Following Transvesical Single-Port Robot-Assisted Radical Prostatectomy: Initial Single Institution Experience. Cancers 2025, 17: 2793. PMID: 40940891, PMCID: PMC12427196, DOI: 10.3390/cancers17172793.
- Makarov D, Thomas J, Ciprut S, Rivera A, Sherman S, Braithwaite R, Best S, Blakely S, D’Agostino L, Dahm P, Dash A, Leapman M, Leppert J, Sanchez A, Shelton J, Tessier C, Tenner C, Gold H, Shedlin M, Zeliadt S. Prostate Cancer Imaging Stewardship: a multimodal, physician-centered intervention for guideline-concordant imaging. Journal Of The National Cancer Institute 2025, 117: 2308-2316. PMID: 40796156, DOI: 10.1093/jnci/djaf210.
- Zurl H, Korn S, Pohl K, Qian Z, Piccolini A, Iyer H, Leapman M, Ahyai S, Shariat S, Trinh Q, Thiel C, Loeb S, Cole A. Estimating the Carbon Emissions of a Single Prostate-specific Antigen Test: Results from a Cradle-to-grave Life Cycle Assessment. European Urology Focus 2025, 11: 1023-1031. PMID: 40753028, DOI: 10.1016/j.euf.2025.07.006.
- Smani S, Wang R, Zhou X, Sprenkle P, Kim I, Dinan M, Gross C, Ma X, Leapman M. Area-Level Social Deprivation and Use of Prostate MRI Before Prostate Biopsy Among Commercial Insurance Beneficiaries. Urology 2025, 205: 145-151. PMID: 40759400, DOI: 10.1016/j.urology.2025.07.070.
- Smani S, Lokeshwar S, Jalfon M, Heckscher D, Press B, Heacock D, Leapman M, Kenney P, Ghali F. Development and Utilization of a Novel Electronic Health Record–Based Care Pathway for Nonmuscle-Invasive Bladder Cancer. Urology Practice 2025, 12: 628-631. PMID: 40637707, DOI: 10.1097/upj.0000000000000872.
- Roessler N, Miszczyk M, Dematteis A, Zattoni F, Fazekas T, Carletti F, Reitano G, Matsukawa A, Alfarhan A, Cormio A, Alqahtani A, Soeterik T, Marvaso G, Gandaglia G, Nyirády P, Rajwa P, Nyk Ł, Palencia P, Leapman M, Jereczek-Fossa B, Shariat S. Prostate radiotherapy in patients with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis of randomised controlled trials. Clinical And Translational Radiation Oncology 2025, 54: 101009. PMID: 40687731, PMCID: PMC12272608, DOI: 10.1016/j.ctro.2025.101009.
- Sundaresan V, Leapman M. Debate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate Cancer. Seminars In Radiation Oncology 2025, 35: 385-392. PMID: 40516973, DOI: 10.1016/j.semradonc.2025.05.001.
- Miszczyk M, Fazekas T, Rajwa P, Matsukawa A, Tsuboi I, Leapman M, Kramer G, Hussain M, Merseburger A, Briganti A, D'Amico A, Gillessen S, Saad F, Shariat S. Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis. European Urology Focus 2025, 11: 755-766. PMID: 40379533, DOI: 10.1016/j.euf.2025.03.019.
- Buck M, Smani S, Nguyen J, Abello A, Jalfon M, Lokeshwar S, Leapman M, Cavallo J, Kenney P. Antibiotic prophylaxis prior to office-based urologic procedures: outcomes from a department-wide quality improvement project. World Journal Of Urology 2025, 43: 257. PMID: 40299076, DOI: 10.1007/s00345-025-05642-0.
- Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Kunst N, Wang S, Ma X, Gross C, Leapman M, Karnes R. Prostate-Specific Membrane Antigen Imaging Findings and Subsequent Clinical Management Among Patients With Biochemically Recurrent Prostate Cancer. JU Open Plus 2025, 3 DOI: 10.1097/ju9.0000000000000278.
- Diaz G, Palencia P, Leapman M. Delivering on the Promise of Precision Oncology in Prostate Cancer: Prediagnostic Strategies, Postdiagnostic Applications, and Future Directions. A Narrative Review. Journal Of Urologic Oncology 2025, 23: 4-13. DOI: 10.22465/juo.255000120006.
- Khajir G, Webb L, Lokeshwar S, Diaz G, Anderson T, Choksi A, Zhao J, Leapman M, Sprenkle P, Renzulli J. Diagnostic performance of high-resolution micro-ultrasound and conventional ultrasound in fusion biopsy for clinically significant prostate cancer detection. Urologic Oncology Seminars And Original Investigations 2025, 43: 399.e1-399.e8. PMID: 40121104, DOI: 10.1016/j.urolonc.2025.03.006.
- McManus H, Long J, Westvold S, Leapman M, Hurwitz M, Mitchell A, Pollack C, Gross C, Dinan M. Off-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2025, 23: 102330. PMID: 40186898, PMCID: PMC12084128, DOI: 10.1016/j.clgc.2025.102330.
- Miszczyk M, Stando R, Francolini G, Zamboglou C, Cadenar A, Suleja A, Fazekas T, Matsukawa A, Tsuboi I, Przydacz M, Leapman M, Rajwa P, Supiot S, Shariat S. Perirectal spacers in radiotherapy for prostate cancer – a systematic review and meta-analysis. Współczesna Onkologia 2025, 29: 36-44. PMID: 40330445, PMCID: PMC12051878, DOI: 10.5114/wo.2025.148388.
- Chen F, Esmaili R, Khajir G, Zeevi T, Gross M, Leapman M, Sprenkle P, Justice A, Arora S, Weinreb J, Spektor M, Huber S, Humphrey P, Levi A, Staib L, Venkataraman R, Martin D, Onofrey J. Comparative Performance of Machine Learning Models in Reducing Unnecessary Targeted Prostate Biopsies. European Urology Oncology 2025, 9: 142-149. PMID: 39924390, PMCID: PMC12332026, DOI: 10.1016/j.euo.2025.01.005.
- Cole A, Qian Z, Gupta N, Leapman M, Zurl H, Trinh Q, Sherman J, Loeb S, Iyer H. Urology on a changing planet: links between climate change and urological disease. Nature Reviews Urology 2025, 22: 208-222. PMID: 39875561, DOI: 10.1038/s41585-024-00979-4.
- Kim I, Leapman M, Kim M, Rahman S, Sprenkle P, Renzulli J, Brito J, Hyams E, Kim J, Pareek G, Kim I. Radical prostatectomy is associated with favorable outcomes in patients over 80 years old. American Journal Of Clinical And Experimental Urology 2025, 13: 33-42. PMID: 40124572, PMCID: PMC11928824, DOI: 10.62347/nkgs2301.
- Ajjawi I, Smani S, Kandala K, Sohoni N, Sutherland R, Washington S, Kim I, Leapman M. Factors associated with time to prostate cancer treatment initiation during the COVID-19 pandemic. American Journal Of Clinical And Experimental Urology 2025, 13: 306-315. PMID: 40978091, PMCID: PMC12444389, DOI: 10.62347/binh7737.
- Sundaresan V, Webb L, Rabil M, Golos A, Sutherland R, Bailey J, Rajwa P, Seibert T, Loeb S, Cooperberg M, Catalona W, Sprenkle P, Kim I, Leapman M. Risks of grade reclassification among patients with Gleason grade group 1 prostate cancer and PI-RADS 5 findings on prostate MRI. Urologic Oncology Seminars And Original Investigations 2024, 43: 193.e19-193.e26. PMID: 39706698, DOI: 10.1016/j.urolonc.2024.11.007.
- Ajjawi I, Loeb S, Cooperberg M, Catalona W, Gross C, Ma X, Leapman M. Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020. JAMA: The Journal Of The American Medical Association 2024, 332: 2033-2036. PMID: 39565605, PMCID: PMC11579888, DOI: 10.1001/jama.2024.20580.
- Sigel K, Yu R, Chiao E, Deshmukh A, Leapman M. Prostate cancer in people with HIV. Current Opinion In Infectious Diseases 2024, 38: 10-17. PMID: 39624951, PMCID: PMC11695140, DOI: 10.1097/qco.0000000000001076.
- Lokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Sutherland R, Brito J, Renzulli J, Sprenkle P, Leapman M. Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy. Urologic Oncology Seminars And Original Investigations 2024, 43: 336.e13-336.e20. PMID: 39521675, DOI: 10.1016/j.urolonc.2024.10.018.
- Marks V, Williams B, Leapman M, Shields C. The Association Between Medical Insurance, Access to Care, and Outcomes for Patients with Uveal Melanoma in the United States. Seminars In Ophthalmology 2024, 40: 223-234. PMID: 39520301, DOI: 10.1080/08820538.2024.2426479.
- Rahman S, Kim H, Webb L, Diaz G, Leapman M, Sprenkle P, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2024, 0: 0-0. PMID: 39697737, PMCID: PMC11651831, DOI: 10.21037/tcr-24-245.
- Washington S, Fakunle M, Wang L, Braun A, Leapman M, Cowan J, Cooperberg M. County-level racial disparities in prostate cancer–specific mortality from 2005 to 2020. JNCI Cancer Spectrum 2024, 8: pkae109. PMID: 39495143, PMCID: PMC11631307, DOI: 10.1093/jncics/pkae109.
- Gaylis F, Leapman M, Ellis S, Hu S, Cooperberg M, Loeb S, Chen R, Cohen E, Dato P, Aynehchi S, David R, Topp R, Santomauro B, Ginsburg K, Catalona W. Feasibility of Pay for Performance and Transparency Interventions on the Selection and Quality of Observational Management for Patients With Low-Risk Prostate Cancer in the Community Practice. Urology Practice 2024, 12: 241-248. PMID: 39453985, DOI: 10.1097/upj.0000000000000745.
- Smani S, Jalfon M, Sundaresan V, Lokeshwar S, Nguyen J, Halstuch D, Khajir G, Cavallo J, Sprenkle P, Leapman M, Kim I. Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? Urologic Oncology Seminars And Original Investigations 2024, 43: 396.e1-396.e7. PMID: 39438211, DOI: 10.1016/j.urolonc.2024.10.002.
- Fazekas T, Pallauf M, Kufel J, Miszczyk M, Tsuboi I, Matsukawa A, Laukhtina E, Kardoust Parizi M, Mancon S, Cadenar A, Schulz R, Yanagisawa T, Baboudjian M, Szarvas T, Gandaglia G, Tilki D, Nyirády P, Rajwa P, Leapman M, Shariat S. Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review. European Urology Oncology 2024, 8: 1352-1364. PMID: 39414421, DOI: 10.1016/j.euo.2024.09.017.
- Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, PMCID: PMC11581571, DOI: 10.1001/jamanetworkopen.2024.40591.
- Sundaresan V, Lokeshwar S, Sutherland R, Sohoni N, Golos A, Ajjawi I, Leapman M. Sociodemographic disparities in prostate cancer imaging. Abdominal Radiology 2024, 51: 1407-1415. PMID: 39325212, DOI: 10.1007/s00261-024-04603-2.
- Press B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, Sprenkle P. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. PMID: 39465014, PMCID: PMC11502073, DOI: 10.37349/etat.2024.00269.
- Rabil M, Leapman M, Cavallo J. Reply to Editorial Comment on “Association of Crowd-Sourced Assessment of Technical Skills and Outcomes of Robotic-assisted Radical Prostatectomy”. Urology 2024, 193: 97-98. PMID: 39208938, DOI: 10.1016/j.urology.2024.08.054.
- Forman R, Long J, Westvold S, Agnish K, McManus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, 8: pkae067. PMID: 39133171, PMCID: PMC11376369, DOI: 10.1093/jncics/pkae067.
- Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024, 8: 1101-1110. PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.
- Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. PMID: 39280242, PMCID: PMC11390291, DOI: 10.37349/etat.2024.00259.
- Sundaresan V, Smani S, Rajwa P, Renzulli J, Sprenkle P, Kim I, Leapman M. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urologic Oncology Seminars And Original Investigations 2024, 43: 41-48. PMID: 39019723, DOI: 10.1016/j.urolonc.2024.06.003.
- Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 11: 965-973. PMID: 39196719, PMCID: PMC12400587, DOI: 10.1097/upj.0000000000000679.
- Rabil M, Jalfon M, Heckscher D, Song Z, Li F, Martin T, Sprenkle P, Hesse D, Kim I, Leapman M, Cavallo J. Association of Crowd-Sourced Assessment of Technical Skills and Outcomes of Robotic-assisted Radical Prostatectomy. Urology 2024, 193: 87-94. PMID: 39019332, DOI: 10.1016/j.urology.2024.07.014.
- Lokeshwar S, Choksi A, Smani S, Ip K, Javier-DesLoges J, Rahman S, Leapman M, Martin T, Hesse D. Classification and Risk Factors for Surgical Site Infections in Radical Cystectomy: A 16-Year Analysis. Surgical Infections 2024, 25: 580-585. PMID: 38959160, PMCID: PMC11807858, DOI: 10.1089/sur.2024.107.
- Diaz G, Webb L, Rabil M, Lokeshwar S, Choksi A, Leapman M, Sprenkle P. Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. Current Urology Reports 2024, 25: 243-252. PMID: 38896314, DOI: 10.1007/s11934-024-01220-w.
- Demkowicz P, Buck M, Nie J, Marks V, Wheeler S, Dinan M, Gross C, Leapman M. Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act. Urology 2024, 192: 19-27. PMID: 38901803, DOI: 10.1016/j.urology.2024.06.003.
- Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.
- Fazekas T, Shim S, Basile G, Baboudjian M, Kói T, Przydacz M, Abufaraj M, Ploussard G, Kasivisvanathan V, Rivas J, Gandaglia G, Szarvas T, Schoots I, van den Bergh R, Leapman M, Nyirády P, Shariat S, Rajwa P. Magnetic Resonance Imaging in Prostate Cancer Screening. JAMA Oncology 2024, 10: 745-754. PMID: 38576242, PMCID: PMC10998247, DOI: 10.1001/jamaoncol.2024.0734.
- Lokeshwar S, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Mehal W, Brito J, Renzulli J, Leapman M. The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy. BMC Urology 2024, 24: 102. PMID: 38702664, PMCID: PMC11067086, DOI: 10.1186/s12894-024-01483-y.
- Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Ellis S, Loeb S, Schulman‐Green D, Leapman M. ‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer. BJUI Compass 2024, 5: 707-715. PMID: 38873351, PMCID: PMC11168777, DOI: 10.1002/bco2.351.
- Rahman S, Long J, Westvold S, Leapman M, Spees L, Hurwitz M, McManus H, Gross C, Wheeler S, Dinan M. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2024, 7: e248747. PMID: 38687479, PMCID: PMC11061765, DOI: 10.1001/jamanetworkopen.2024.8747.
- Zeevi T, Leapman M, Sprenkle P, Venkataraman R, Staib L, Onofrey J. Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy Histopathology. IEEE Transactions On Biomedical Engineering 2024, 71: 1084-1091. PMID: 37874731, PMCID: PMC10901528, DOI: 10.1109/tbme.2023.3326799.
- Kim I, Wang A, Corpuz G, Sprenkle P, Leapman M, Brito J, Renzulli J, Kim I. Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy. Prostate International 2024, 12: 70-78. PMID: 39036758, PMCID: PMC11255894, DOI: 10.1016/j.prnil.2024.01.002.
- Justice A, Tate J, Howland F, Gaziano J, Kelley M, McMahon B, Haiman C, Wadia R, Madduri R, Danciu I, Leppert J, Leapman M, Thurtle D, Gnanapragasam V. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer. European Urology Oncology 2024, 7: 923-932. PMID: 38171965, DOI: 10.1016/j.euo.2023.11.023.
- Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco J, Washington S, Renzulli J, Sprenkle P, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urologic Oncology Seminars And Original Investigations 2023, 42: 28.e9-28.e20. PMID: 38161105, DOI: 10.1016/j.urolonc.2023.10.005.
- Marks V, Hsiang W, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar M, Pantel H, Berger E, Boffa D, Cavallo J, Leapman M. Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study. JMIR Cancer 2023, 9: e45518. PMID: 37917149, PMCID: PMC10654905, DOI: 10.2196/45518.
- Heckscher D, Jalfon M, Buck M, Abello A, Nguyen J, Casilla-Lennon M, Leapman M, Hittelman A, Teitelbaum J, Emerson B, Kenney P, Cavallo J, Lambert S. Implementation of a health system intervention to reduce time from presentation to surgical intervention for pediatric testicular torsion. Journal Of Pediatric Urology 2023, 20: 254.e1-254.e7. PMID: 38030428, DOI: 10.1016/j.jpurol.2023.10.042.
- Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.
- Baum L, KC M, Soulos P, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Trends in new and persistent opioid use in older adults with and without cancer. Journal Of The National Cancer Institute 2023, 116: 316-323. PMID: 37802882, PMCID: PMC13032033, DOI: 10.1093/jnci/djad206.
- Leapman M. Embracing Challenges and Opportunities Posed by New Technologies in Urologic Care. Urology Practice 2023, 11: 7-8. PMID: 37747948, DOI: 10.1097/upj.0000000000000459.
- Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancerLeapman M, Sutherland R, Gross C, Ma X, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman‐Green D. Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer. BJUI Compass 2023, 5: 142-149. PMID: 38179031, PMCID: PMC10764160, DOI: 10.1002/bco2.277.
- Ślusarczyk A, Baboudjian M, Zapała P, Yanagisawa T, Miszczyk M, Chlosta M, Krumpoeck P, Moschini M, Gandaglia G, Ploussard G, Rivas J, Życzkowski M, Karakiewicz P, Radziszewski P, Leapman M, Shariat S, Rajwa P. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations. The Prostate 2023, 83: 1504-1515. PMID: 37545342, DOI: 10.1002/pros.24609.
- Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.
- Jalfon M, Sakhalkar O, Lokeshwar S, Marks V, Choksi A, Klaassen Z, Leapman M, Kim I. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer. Current Urology Reports 2023, 24: 455-461. PMID: 37369828, DOI: 10.1007/s11934-023-01173-6.
- Lokeshwar S, Choksi A, Haltstuch D, Rahman S, Press B, Syed J, Hurwitz M, Kim I, Leapman M. Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics. World Journal Of Urology 2023, 41: 2007-2019. PMID: 37160450, DOI: 10.1007/s00345-023-04409-9.
- Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum 2023, 7: pkad036. PMID: 37202354, PMCID: PMC10276895, DOI: 10.1093/jncics/pkad036.
- Leapman M, Loeb S, Cooperberg M, Catalona W, Gaylis F. A vision for closing the evidence-practice gap in the management of low-grade prostate cancer. JNCI Cancer Spectrum 2023, 7: pkad028. PMID: 37101361, PMCID: PMC10133397, DOI: 10.1093/jncics/pkad028.
- Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.
- Laditi F, Nie J, Hsiang W, Umer W, Haleem A, Marks V, Buck M, Leapman M. Access to urologic cancer care for Medicaid-insured patients. Urologic Oncology Seminars And Original Investigations 2023, 41: 206.e21-206.e27. PMID: 36740488, DOI: 10.1016/j.urolonc.2023.01.014.
- Leapman M, Thiel C, Gordon I, Nolte A, Perecman A, Loeb S, Overcash M, Sherman J. Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy. European Urology 2023, 83: 463-471. PMID: 36635108, DOI: 10.1016/j.eururo.2022.12.008.
- Chu C, Leapman M, Zhao S, Cowan J, Washington S, Cooperberg M. Prostate cancer disparities among American Indians and Alaskan Natives in the United States. Journal Of The National Cancer Institute 2023, 115: 413-420. PMID: 36629492, PMCID: PMC10086629, DOI: 10.1093/jnci/djad002.
- Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman M, Gore J, Paradysz A, Tilki D, Merseburger A, Morgan T, Briganti A, Palapattu G, Shariat S. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology 2023, 20: 205-216. PMID: 36600087, DOI: 10.1038/s41585-022-00680-4.
- Rahman S, Lokeshwar S, Syed J, Javier-Desloges J, Press B, Choksi A, Rajwa P, Pradere B, Ploussard G, Kim J, Monaghan T, Renzulli J, Shariat S, Leapman M. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. Urologic Oncology Seminars And Original Investigations 2022, 41: 107.e1-107.e8. PMID: 36481253, DOI: 10.1016/j.urolonc.2022.09.008.
- Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncology Practice 2022, 19: e213-e227. PMID: 36413741, PMCID: PMC9970274, DOI: 10.1200/op.22.00401.
- Nabavizadeh B, Li KD, Hakam N, Shaw NM, Leapman MS, Breyer BN. Incidence of circumcision among insured adults in the United States. PLOS ONE 2022, 17: e0275207. PMID: 36251658, PMCID: PMC9576047, DOI: 10.1371/journal.pone.0275207.
- Marks VA, Hsiang WR, Nie J, Demkowicz P, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar MC, Berger ER, Boffa DJ, Leapman MS. Acceptance of Simulated Adult Patients With Medicaid Insurance Seeking Care in a Cancer Hospital for a New Cancer Diagnosis. JAMA Network Open 2022, 5: e2222214. PMID: 35838668, PMCID: PMC9287756, DOI: 10.1001/jamanetworkopen.2022.22214.
- Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.
- Holler J, Hakam N, Nabavizadeh B, Sadighian M, Shibley W, Li K, Weiser L, Rios N, Enriquez A, Leapman M, Amend G, Breyer B. Characteristics of Online Crowdfunding Campaigns for Urological Cancers in the United States. Urology Practice 2021, 9: 56-63. PMID: 37145560, PMCID: PMC12721642, DOI: 10.1097/upj.0000000000000275.
- Nie J, Demkowicz P, Hsiang W, Umer W, Chen E, McMahon G, Kenney P, Breyer B, Parikh R, Leapman M. Urology Practice Acquisitions by Private Equity Firms from 2011–2021. Urology Practice 2021, 9: 17-24. PMID: 37145557, DOI: 10.1097/upj.0000000000000269.
- Nie J, Demkowicz P, Hsiang W, Umer W, Chen E, McMahon G, Kenney P, Breyer B, Parikh R, Leapman M. Reply by Authors. Urology Practice 2021, 9: 24-24. PMID: 37145588, DOI: 10.1097/upj.0000000000000269.02.
- Advani S, Gao C, Datta R, Sann L, Smith C, Leapman MS, Hittelman A, Sabetta J, Dembry LM, Martinello RA, Juthani-Mehta M. Knowledge and Practices of Physicians and Nurses related to Urine Cultures in Catheterized Patients: An Assessment of Adherence to IDSA Guidelines. Open Forum Infectious Diseases 2019, 6: ofz305. PMID: 31375836, PMCID: PMC6677670, DOI: 10.1093/ofid/ofz305.
- Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate CancerLeapman MS, Wang R, Park HS, Yu JB, Weinreb JC, Gross CP, Ma X. Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. Urology 2018, 124: 98-106. PMID: 30107188, DOI: 10.1016/j.urology.2018.07.041.
- Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll PR. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PLOS ONE 2017, 12: e0185535. PMID: 29016610, PMCID: PMC5634556, DOI: 10.1371/journal.pone.0185535.
- Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR. Active Surveillance in Younger Men With Prostate Cancer. Journal Of Clinical Oncology 2017, 35: jco.2016.68.005. PMID: 28346806, PMCID: PMC5466007, DOI: 10.1200/jco.2016.68.0058.
- Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer OutcomesLeapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. European Urology 2016, 71: 750-759. PMID: 27940155, DOI: 10.1016/j.eururo.2016.11.032.
- Leapman M, Carroll P. Risk Stratification of Newly Diagnosed Prostate Cancer with Genomic Platforms. Urology Practice 2016, 4: 322-328. PMID: 37592678, DOI: 10.1016/j.urpr.2016.06.008.
- Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal Of Urology 2016, 196: 1408-1414. PMID: 27352635, PMCID: PMC5542578, DOI: 10.1016/j.juro.2016.06.086.
- Leapman M, Shinohara K. TRUS Biopsy: Is There Still a Role? 2016, 53-67. DOI: 10.1007/978-3-319-21485-6_4.
- Leapman M, Cooperberg M. Clinical Risk Prediction Tools for Prostate Cancer: TNM to CAPRA—Should Risk Be Redefined? 2016, 33-52. DOI: 10.1007/978-3-319-21485-6_3.
- Polland A, Leapman M, Stone N. A Case-Based Illustration of Urinary Symptoms Following Radiation Therapy for Prostate Cancer. 2015, 151-172. DOI: 10.1007/978-3-319-23817-3_11.
- Leapman M, Stone N. Urinary Retention and Incontinence after Low-Dose-Rate Brachytherapy for Prostate Cancer. Current Bladder Dysfunction Reports 2013, 8: 236-241. DOI: 10.1007/s11884-013-0188-5.
- Yale UrologyYale Physicians Building800 Howard AvenueNew Haven, CT 06519
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale UrologyYale Physicians Building800 Howard AvenueNew Haven, CT 06519
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510